Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
Intrinsic Value
Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical products. [ Read More ]
The intrinsic value of one
Tianjin Chase Sun Pharmaceutical Co Ltd
stock under the Base Case scenario is
5.04
CNY.
Compared to the current market price of 3.74 CNY,
Tianjin Chase Sun Pharmaceutical Co Ltd
is
Undervalued by 26%.
Tianjin Chase Sun Pharmaceutical Co Ltd's market capitalization is 11.2B CNY.
Tianjin Chase Sun Pharmaceutical Co Ltd stock price is 3.74 CNY.
Tianjin Chase Sun Pharmaceutical Co Ltd stock price (3.74 CNY) is 26% less than its Intrinsic Value (5.04 CNY).
Tianjin Chase Sun Pharmaceutical Co Ltd stock price (3.74 CNY) is 36% less than its DCF Value (5.85 CNY). Open DCF Valuation
Tianjin Chase Sun Pharmaceutical Co Ltd stock price (3.74 CNY) is 12% less than its Relative Value (4.23 CNY). Open Relative Valuation
Tianjin Chase Sun Pharmaceutical Co Ltd has upside potential of 472% compared to the average analyst price target.
Open Wall St Estimates
Tianjin Chase Sun Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Tianjin Chase Sun Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Tianjin Chase Sun Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Tianjin Chase Sun Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 9% to 6%.
Tianjin Chase Sun Pharmaceutical Co Ltd's Revenue has been falling by 2% per year for the last 3 years.
Tianjin Chase Sun Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 6%.
Tianjin Chase Sun Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 9% to 5%.
Tianjin Chase Sun Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 8%. The company is efficient at transforming stockholders' equity into net income.
Tianjin Chase Sun Pharmaceutical Co Ltd's Revenue has dropped by 8% over the past 12 months.
Tianjin Chase Sun Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
Tianjin Chase Sun Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
Tianjin Chase Sun Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (1B CNY).
Tianjin Chase Sun Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Tianjin Chase Sun Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.16.
Tianjin Chase Sun Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 4.1.
Tianjin Chase Sun Pharmaceutical Co Ltd's long-term assets (12B CNY) exceed its long-term liabilties (3B CNY).
Tianjin Chase Sun Pharmaceutical Co Ltd's short-term assets (7B CNY) exceed its short-term liabilties (2B CNY).
Valuation Backtest
Tianjin Chase Sun Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Tianjin Chase Sun Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Tianjin Chase Sun Pharmaceutical Co Ltd
Balance Sheet Decomposition
Tianjin Chase Sun Pharmaceutical Co Ltd
| Current Assets | 6.7B |
| Cash & Short-Term Investments | 1.5B |
| Receivables | 3B |
| Other Current Assets | 2.1B |
| Non-Current Assets | 5.1B |
| Long-Term Investments | 247.6m |
| PP&E | 3.3B |
| Intangibles | 1.4B |
| Other Non-Current Assets | 236.8m |
| Current Liabilities | 1.6B |
| Accounts Payable | 666.1m |
| Accrued Liabilities | 55.7m |
| Short-Term Debt | 86.8m |
| Other Current Liabilities | 756.1m |
| Non-Current Liabilities | 1.6B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 243.5m |
Earnings Waterfall
Tianjin Chase Sun Pharmaceutical Co Ltd
|
Revenue
|
6.1B
CNY
|
|
Cost of Revenue
|
-2.8B
CNY
|
|
Gross Profit
|
3.3B
CNY
|
|
Operating Expenses
|
-2.7B
CNY
|
|
Operating Income
|
553m
CNY
|
|
Other Expenses
|
-46.3m
CNY
|
|
Net Income
|
506.6m
CNY
|
Free Cash Flow Analysis
Tianjin Chase Sun Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Tianjin Chase Sun Pharmaceutical Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Tianjin Chase Sun Pharmaceutical Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Tianjin Chase Sun Pharmaceutical Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Tianjin Chase Sun Pharmaceutical Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Tianjin Chase Sun Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Tianjin Chase Sun Pharmaceutical Co Ltd
is 21.4 CNY
.
Shareholder Return
Price
Tianjin Chase Sun Pharmaceutical Co Ltd
| Average Annual Return | 21.15% |
| Standard Deviation of Annual Returns | 42.81% |
| Max Drawdown | -65% |
| Market Capitalization | 11.1B CNY |
| Shares Outstanding | 3 004 154 837 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Tianjin Chase Sun Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Tianjin Chase Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 6,120 full-time employees. The company went IPO on 2009-10-30. The firm's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The firm also provides medical apparatus and instrument. The firm distributes its products in domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Tianjin Chase Sun Pharmaceutical Co Ltd
stock under the Base Case scenario is
5.04
CNY.
Compared to the current market price of 3.74 CNY,
Tianjin Chase Sun Pharmaceutical Co Ltd
is
Undervalued by 26%.
You don't have any saved screeners yet
